Business & Finance

Microbix reports sales growth, product and infrastructure investment in FY06

Published in Vaccine Weekly, January 17th, 2007

Microbix Biosystems Inc. (MBX) announced in its financial results for the year ended September 30, 2006, that the company continued to seek partnering opportunities for the urokinase and vaccine technologies in 2006, and made significant investment the company's pipeline development and manufacturing capacity in anticipation of utilization of these core assets.

The company also continues to expand development of the semen sexing technology, has acquired the urokinase manufacturing facility from Merck KgaA, and laid additional groundwork for building value in the vaccine technology. Net loss for fiscal 2006 was $2,092,022 or 6 cents per share, compared to $125,526 or...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2007-01-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry